BR112017008852A2 - tiazóis substituídos com amida como moduladores do roryt - Google Patents

tiazóis substituídos com amida como moduladores do roryt

Info

Publication number
BR112017008852A2
BR112017008852A2 BR112017008852-5A BR112017008852A BR112017008852A2 BR 112017008852 A2 BR112017008852 A2 BR 112017008852A2 BR 112017008852 A BR112017008852 A BR 112017008852A BR 112017008852 A2 BR112017008852 A2 BR 112017008852A2
Authority
BR
Brazil
Prior art keywords
amide substituted
substituted thiazoles
compound
roryt modulators
syndrome
Prior art date
Application number
BR112017008852-5A
Other languages
English (en)
Inventor
Goldberg Steven
Venkatesan Hariharan
Tanis Virginia
Urbanski Maud
Wang Aihua
Kummer David
Steeneck Christoph
Gege Christian
Kinzel Olaf
Kleymann Gerald
Hoffmann Thomas
M. Fourie Anne
Xue Xiaohua
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of BR112017008852A2 publication Critical patent/BR112017008852A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

a presente invenção compreende compostos de fórmula i. fórmula i em que: r1, r2, r3, r5, a1, a2 e são definidos no relatório descritivo. a invenção também compreende um composto de fórmula i para uso em um método de tratamento ou melhoria de uma síndrome, distúrbio ou doença, sendo que a dita síndrome, distúrbio ou doença é artrite reumatoide ou psoríase. a invenção também compreende um composto para uso em um método de modulação da atividade de ror¿t em um mamífero por meio da administração de uma quantidade terapeuticamente eficaz de pelo menos um composto de acordo com a reivindicação 1.
BR112017008852-5A 2014-10-30 2015-10-30 tiazóis substituídos com amida como moduladores do roryt BR112017008852A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462072599P 2014-10-30 2014-10-30
US62/072,599 2014-10-30
PCT/US2015/058200 WO2016069978A1 (en) 2014-10-30 2015-10-30 AMIDE SUBSTITUTED THIAZOLES AS MODULATORS OF RORγT

Publications (1)

Publication Number Publication Date
BR112017008852A2 true BR112017008852A2 (pt) 2018-01-16

Family

ID=54542554

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017008852-5A BR112017008852A2 (pt) 2014-10-30 2015-10-30 tiazóis substituídos com amida como moduladores do roryt

Country Status (21)

Country Link
US (1) US9845319B2 (pt)
EP (1) EP3212642B1 (pt)
JP (1) JP6695335B2 (pt)
KR (1) KR20170075787A (pt)
CN (1) CN108064224B (pt)
AU (1) AU2015339091B2 (pt)
BR (1) BR112017008852A2 (pt)
CA (1) CA2965518A1 (pt)
CY (1) CY1122563T1 (pt)
DK (1) DK3212642T3 (pt)
ES (1) ES2767303T3 (pt)
HK (1) HK1243418A1 (pt)
HR (1) HRP20200016T1 (pt)
HU (1) HUE046888T2 (pt)
IL (1) IL251857B (pt)
MA (1) MA40865B1 (pt)
PL (1) PL3212642T3 (pt)
PT (1) PT3212642T (pt)
RS (1) RS59752B1 (pt)
SI (1) SI3212642T1 (pt)
WO (1) WO2016069978A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200117A1 (ar) 2014-10-30 2017-06-16 Janssen Pharmaceutica Nv كحولات ثلاثي فلوروميثيل كمُعدلات للمستقبل النووي جاما تي المرتبط بحمض الريتيونَويك ROR?t
PL3212641T3 (pl) 2014-10-30 2019-05-31 Janssen Pharmaceutica Nv Tiazole jako modulatory RORYT
TW201803869A (zh) 2016-04-27 2018-02-01 健生藥品公司 作為ＲＯＲγＴ調節劑之６－胺基吡啶－３－基噻唑
BR112020018718A2 (pt) 2018-03-12 2021-03-09 Escalier Biosciences B.V. Moduladores de ror-gama espirocíclicos
EP3765009A4 (en) * 2018-03-12 2021-11-10 Escalier Biosciences, BV BICYCLIC ROR-GAMMA MODULATORS
EP3807261B1 (en) 2018-06-18 2022-07-13 Janssen Pharmaceutica NV Pyridinyl pyrazoles as modulators of roryt
EP3807251B1 (en) 2018-06-18 2022-09-07 Janssen Pharmaceutica NV Phenyl and pyridinyl substituted imidazoles as modulators of roryt
WO2019243965A1 (en) * 2018-06-18 2019-12-26 Janssen Pharmaceutica Nv Pyrazole derivatives as malt1 inhibitors
ES2928246T3 (es) * 2018-06-18 2022-11-16 Janssen Pharmaceutica Nv 6-aminopiridin-3-il pirazoles como moduladores de RORyt
CA3103929A1 (en) * 2018-06-18 2019-12-26 Janssen Pharmaceutica Nv Phenyl substituted pyrazoles as modulators of roryt

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL91418A (en) 1988-09-01 1997-11-20 Rhone Poulenc Agrochimie (hetero) cyclic amide derivatives, process for their preparation and fungicidal compositions containing them
EP0772606A1 (en) 1994-07-27 1997-05-14 G.D. SEARLE & CO. Substituted thiazoles for the treatment of inflammation
PL367325A1 (en) 2001-04-16 2005-02-21 Tanabe Seiyaku Co, Ltd. Large conductance calcium-activated k channel opener
EP1418911B1 (en) * 2001-08-13 2006-05-10 Janssen Pharmaceutica N.V. 2,4,5-trisubstituted thiazolyl derivatives and their antiinflammatory activity
MXPA04002931A (es) * 2001-10-12 2005-04-11 Bayer Pharmaceuticals Corp Heterociclos que contienen nitrogeno de 5 miembros sustituidos con fenilo para el tratamiento de la obesidad.
US8188128B2 (en) 2005-05-12 2012-05-29 The University Of Medicine And Dentistry Of New Jersey Opioid receptor subtype-selective agents
CA2639910A1 (en) 2006-01-25 2007-08-02 Synta Pharmaceuticals Corp. Thiazole and thiadiazole compounds for inflammation and immune-related uses
WO2008064317A1 (en) 2006-11-22 2008-05-29 University Of Medicine And Dentistry Of New Jersey Lipophilic opioid receptor active compounds
WO2008064318A2 (en) 2006-11-22 2008-05-29 University Of Medicine And Dentistry Of New Jersey Peripheral opioid receptor active compounds
US20090069288A1 (en) 2007-07-16 2009-03-12 Breinlinger Eric C Novel therapeutic compounds
US8809547B2 (en) 2008-07-17 2014-08-19 Bayer Cropscience Ag Heterocyclic compounds as pesticides
AR079022A1 (es) 2009-11-02 2011-12-21 Sanofi Aventis Derivados de acido carboxilico ciclico sustituidos con acilamino, su uso como productos farmaceuticos, composicion farmaceutica y metodo de preparacion
US9101600B2 (en) 2010-03-11 2015-08-11 New York University Compounds as RORγt modulators and uses thereof
ES2703176T3 (es) 2010-03-11 2019-03-07 Univ New York Compuestos amido como moduladores de RORgammat y usos de los mismos
WO2011115892A1 (en) 2010-03-15 2011-09-22 Griffin Patrick R Modulators of the retinoic acid receptor-related orphan receptors
WO2012027965A1 (en) 2010-09-01 2012-03-08 Glaxo Group Limited Novel compounds
US9505798B2 (en) 2010-11-29 2016-11-29 New York University Steroid compounds as RORyt modulators and uses thereof
KR101958699B1 (ko) 2010-12-28 2019-03-15 라이온 가부시키가이샤 구강 상태의 판정 방법, 그리고 그것을 위해 사용되는 분석 용구, 장치, 및 프로그램
US9012651B2 (en) 2011-03-24 2015-04-21 Abbvie Inc. TRPV3 modulators
US9586928B2 (en) 2011-05-16 2017-03-07 The Scripps Research Institute Modulators of the nuclear hormone receptor ROR
US9156837B2 (en) 2011-07-29 2015-10-13 Takeda Pharmaceutical Company Limited Heterocyclic compound
SG11201400456RA (en) 2011-09-09 2014-04-28 Univ New York Amido compounds as ror?tmodulators and uses thereof
JP5918859B2 (ja) 2011-12-02 2016-05-18 フェネックス ファーマシューティカルス アーゲー オーファン核内受容体ＲＡＲに関連するオーファン受容体−ガンマ（ＲＯＲγ、ＮＲ１Ｆ３）活性の調整剤としての、慢性の炎症性疾患および自己免疫性疾患を治療するためのピロロカルボキサミド
US20130190356A1 (en) 2011-12-22 2013-07-25 Genentech, Inc. Benzyl sulfonamide derivatives as rorc modulators
SG11201407919WA (en) 2012-05-31 2014-12-30 Phenex Pharmaceuticals Ag Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators for the orphan nuclear receptor ror[gamma]
WO2015035278A1 (en) 2013-09-09 2015-03-12 Bristol-Myers Squibb Company RORγ MODULATORS
US20150072890A1 (en) 2013-09-11 2015-03-12 20/20 Gene Systems, Inc. Methods and compositions for aiding in the detection of lung cancer
CN105555768B (zh) 2013-09-20 2018-10-16 百时美施贵宝公司 RORγ调节剂
RS58650B1 (sr) 2013-12-05 2019-05-31 Lead Pharma Holding Bv Ror gama (rory) modulatori
US20160326108A1 (en) 2014-01-06 2016-11-10 Bristol-Myers Squibb Company Pyrrolidinyl sulfone derivatives and their use as ror gamma modulators
US9637455B2 (en) 2014-01-06 2017-05-02 Bristol-Myers Squibb Company Heterocyclic sulfone RORγ modulators
ES2704460T3 (es) 2014-01-06 2019-03-18 Bristol Myers Squibb Co Moduladores de ROR gamma de ciclohexilsulfona
CN106132931B (zh) 2014-01-06 2019-08-02 百时美施贵宝公司 碳环砜RORγ调节剂
EP3122721A4 (en) 2014-03-27 2018-01-10 Piramal Enterprises Limited Ror-gamma modulators and uses thereof
CN103833672A (zh) * 2014-03-28 2014-06-04 中国药科大学 一种n-丁基-5-苯基噻唑-4-甲酰胺类衍生物的制备方法

Also Published As

Publication number Publication date
CN108064224B (zh) 2022-03-29
HRP20200016T1 (hr) 2020-03-20
DK3212642T3 (da) 2019-11-25
WO2016069978A1 (en) 2016-05-06
AU2015339091B2 (en) 2020-05-28
EP3212642B1 (en) 2019-10-30
US20160122335A1 (en) 2016-05-05
CN108064224A (zh) 2018-05-22
JP2018500286A (ja) 2018-01-11
CY1122563T1 (el) 2021-01-27
IL251857B (en) 2020-09-30
EP3212642A1 (en) 2017-09-06
HUE046888T2 (hu) 2020-03-30
RS59752B1 (sr) 2020-02-28
HK1243418A1 (zh) 2018-07-13
MA40865B1 (fr) 2019-11-29
ES2767303T3 (es) 2020-06-17
CA2965518A1 (en) 2016-05-06
JP6695335B2 (ja) 2020-05-20
KR20170075787A (ko) 2017-07-03
US9845319B2 (en) 2017-12-19
SI3212642T1 (sl) 2020-01-31
PT3212642T (pt) 2019-12-19
IL251857A0 (en) 2017-06-29
PL3212642T3 (pl) 2020-04-30
AU2015339091A1 (en) 2017-05-11

Similar Documents

Publication Publication Date Title
BR112017008852A2 (pt) tiazóis substituídos com amida como moduladores do roryt
BR112017008842A2 (pt) tiazóis como moduladores de ror?t
BR112017008816A2 (pt) álcoois trifluormetílicos como moduladores do roryt
BR112016008258A2 (pt) moduladores de ror?t de quinolinila
BR112018070602A2 (pt) composto, composição farmacêutica, uso do composto, e, método para tratar uma doença ou distúrbio
NI201800109A (es) TIAZOLES DE 6-AMINOPIRIDIN-3-IL COMO MODULADORES DE RORyT
UY35084A (es) MODULADORES DE RORyt DE QUINOLINILO UNIDOS POR METILENO
CL2016001595A1 (es) Moduladores de tetrahidropiridopirazinas de gpr6.
PH12015500776A1 (en) Phenyl linked quinolinyl modulators of ror-gamma-t
BR112017028194A2 (pt) moduladores de diaciglicerol aciltransferase 2 (dgat2)
PH12016502062A1 (en) Compositions and methods for modulating completent factor b expression
BR112018075736A2 (pt) composto de amida alfa e beta insaturado derivado de benzotriazol usado como inibidor de tgf-betar1
CL2016000019A1 (es) Compuestos derivados de dihidroxifenilo deuterado o una sal de los mismos; composición farmacéutica que los comprende y su uso para el tratamiento de trastornos mediados por neurotransmisores tales como hipotensión, trastornos del sueño, enfermedad de alzheimer y depresión.
BR112015006727A8 (pt) uso de uma composição farmacêutica
BR112016008215A2 (pt) moduladores de quinolinila ligados por alquila de roryt
BR112016008201A2 (pt) Moduladores de quinolinila ligados à heteroarila de roryt
BR112016008257A2 (pt) moduladores de roryt de álcool quinolínico secundário
BR112015025968A2 (pt) poliplexos
BR112016008183A2 (pt) Moduladores de ror-gama-t de quinolinila ligados à fenila

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements